Inositol nicotinate — answers to inositol hexanicotinate
Hasn’t appeared in a scanned product yet.
Talk to your doctor or pharmacist.
Roll Call does not check drug interactions or assess personal safety.
A compound formed by combining inositol with nicotinic acid (niacin), sometimes called "no-flush niacin" because it is believed to release niacin more slowly and with less of the skin-flushing reaction associated with plain niacin.
Why it’s used
Taken as an alternative form of niacin, historically used with the aim of supporting circulation, including in claudication (leg pain from reduced blood flow), and sometimes for cholesterol-related purposes.
What the evidence is for
claimed circulatory benefit in intermittent claudication.
What the evidence says
The only cited study is a 6-week trial in adults with mild-to-moderate dyslipidemia comparing wax-matrix niacin, inositol hexanicotinate, and placebo on cholesterol and lipid blood chemistry; it does not examine intermittent claudication, walking distance, or any circulatory outcome. The trial did find that inositol hexanicotinate produced no significant lipid changes versus placebo and showed no measurable bioavailability in a pharmacokinetic substudy, but this speaks to lipid effects and absorption, not to circulatory symptoms in claudication. No passage in the source addresses the claimed circulatory benefit population or outcome.
Context
Trials reviewed used varying doses over periods of weeks to months, with inconsistent methods and outcome measures, which the review cited as a reason firm conclusions could not be drawn.
Educational information, not medical or safety advice. Consult a professional for allergies or medical concerns.